Phase II Study of Interleukin-4 in Indolent B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia: A Study of the Eastern Cooperative Oncology Group (E5Y92)

被引：7

作者：

Wiernik, Peter H. ^{[1
,2
]}

Dutcher, Janice P. ^{[1
,2
]}

Yao, Xiapan ^{[2
,3
]}

Venkatraj, Usha ^{[1
,2
]}

Falkson, Carla I. ^{[2
,4
]}

Rowe, Jacob M. ^{[2
,6
]}

Cassileth, Peter A. ^{[2
,5
]}

机构：

[1] New York Med Coll, Valhalla, NY 10595 USA

[2] Eastern Cooperat Grp, Cambridge, England

[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA

[4] Univ Alabama, Birmingham, AL USA

[5] Univ Miami, Sylvester Canc Ctr, Miami, FL USA

[6] Rambam Med Ctr, Haifa, Israel

来源：

JOURNAL OF IMMUNOTHERAPY | 2010年 / 33卷 / 09期

基金：

美国国家卫生研究院;

关键词：

interleukin-4; interleukin-6; low-grade lymphoma; chronic lymphocytic leukemia; RECOMBINANT HUMAN INTERLEUKIN-4; IL-4; THERAPY; TRIAL; TOXICITY; CANCER;

D O I：

10.1097/CJI.0b013e3181f5dfc5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recombinant interleukin (IL)-4, 5 mu g/kg thrice weekly for 3 weeks followed by a 2-week rest period (1 cycle) was administered to 32 eligible previously treated B-cell chronic lymphocytic leukemia (7 patients) or low-grade B-cell lymphoma patients (25 patients). Two cycles were given before response was evaluated. IL-6 serum levels were evaluated before therapy in all patients and at 12 weeks on study in 7 patients. None of the chronic lymphocytic leukemia patients responded. A partial response was observed in 3 lymphoma patients of 1.2, 3.0, and 3.5 months' duration and stable disease (median 1.5mo) was observed in another 7 lymphoma patients. The median survival from registration on study was 29.7 months with 7 patients alive at the time of analysis for a median follow-up of 72.8 months. Toxicity was generally mild with no grade 4 nonhematologic toxicity observed. Recombinant IL-4 treatment was well tolerated in this study but had minimal antitumor activity.

引用

页码：1006 / 1009

页数：4

共 50 条

[21] Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent. non-Hodgkin's lymphoma [J].

Van den Neste, E ;

Louviaux, I ;

Michaux, JL ;

Delannoy, A ;

Michaux, L ;

Sonet, A ;

Bosly, A ;

Doyen, C ;

Mineur, P ;

André, M ;

Straetmans, N ;

Coche, E ;

Venet, C ;

Duprez, T ;

Ferrant, A .

LEUKEMIA, 2000, 14 (06) :1136-1142

[22] A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy [J].

Goy, Andre ;

Forero, Andres ;

Wagner-Johnston, Nina ;

Ehmann, W. Christopher ;

Tsai, Michaela ;

Hatake, Kiyohiko ;

Ananthakrishnan, Revathi ;

Volkert, Angela ;

Vandendries, Erik ;

Ogura, Michinori .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (04) :571-581

[23] Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402 [J].

Williams, Michael E. ;

Hong, Fangxin ;

Gascoyne, Randy D. ;

Wagner, Lynne I. ;

Krauss, John C. ;

Habermann, Thomas M. ;

Swinnen, Lode J. ;

Schuster, Stephen J. ;

Peterson, Christopher G. ;

Sborov, Mark D. ;

Martin, S. Eric ;

Weiss, Matthias ;

Ehmann, W. Christopher ;

Horning, Sandra J. ;

Kahl, Brad S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (06) :867-875

[24] SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target [J].

Christensen, Dale J. ;

Chen, Youwei ;

Oddo, Jessica ;

Matta, Karen M. ;

Neil, Jessica ;

Davis, Evan D. ;

Volkheimer, Alicia D. ;

Lanasa, Mark C. ;

Friedman, Daphne R. ;

Goodman, Barbara K. ;

Gockerman, Jon P. ;

Diehl, Louis F. ;

de Castro, Carlos M. ;

Moore, Joseph O. ;

Vitek, Michael P. ;

Weinberg, J. Brice .

BLOOD, 2011, 118 (15) :4150-4158

[25] Improved Treatment Results of Children With B-Cell Non-Hodgkin Lymphoma: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study [J].

Tsurusawa, Masahito ;

Mori, Tetsuya ;

Kikuchi, Akira ;

Mitsui, Tetsuo ;

Sunami, Shosuke ;

Kobayashi, Ryoji ;

Takimoto, Tetsuya ;

Saito, Akiko ;

Watanabe, Tomoyuki ;

Fujimoto, Junichiro ;

Nakazawa, Atsuko ;

Ohshima, Kouichi ;

Horibe, Keizo .

PEDIATRIC BLOOD & CANCER, 2014, 61 (07) :1215-1221

[26] CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences [J].

Vitale, Candida ;

Strati, Paolo .

FRONTIERS IN ONCOLOGY, 2020, 10

[27] A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan [J].

Ishizawa, Kenichi ;

Yokoyama, Masahiro ;

Kato, Harumi ;

Yamamoto, Kazuhito ;

Makita, Masanori ;

Ando, Kiyoshi ;

Ueda, Yasunori ;

Tachikawa, Yoshimichi ;

Suehiro, Youko ;

Kurosawa, Mitsutoshi ;

Kameoka, Yoshihiro ;

Nagai, Hirokazu ;

Uoshima, Nobuhiko ;

Ishikawa, Takayuki ;

Hidaka, Michihiro ;

Ito, Yoshikiyo ;

Utsunomiya, Atae ;

Fukushima, Koji ;

Ogura, Michinori .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (01) :83-95

[28] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma [J].

Hamadani, Mehdi ;

Radford, John ;

Carlo-Stella, Carmelo ;

Caimi, Paolo F. ;

Reid, Erin ;

O'Connor, Owen A. ;

Feingold, Jay M. ;

Ardeshna, Kirit M. ;

Townsend, William ;

Solh, Melhem ;

Heffner, Leonard T. ;

Ungar, David ;

Wang, Luqiang ;

Boni, Joseph ;

Havenith, Karin ;

Qin, Yajuan ;

Kahl, Brad S. .

BLOOD, 2021, 137 (19) :2634-2645

[29] Safety of Bendamustine for the Treatment of Patients with B-Cell Non-Hodgkin Lymphoma, a Retrospective Cohort Study [J].

Cristaldo, Nancy ;

Warley, Fernando ;

Fantl, Dorotea ;

Basquiera, Ana ;

Otero, Victoria .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 :S292-S292

[30] Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development [J].

Kubuschok, Boris ;

Trepel, Martin .

EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (07) :733-745

← 1 2 3 4 5 →